Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|November 4, 2019
Bipolar Research Update: Risks and More Risks
Author(s)Leo Robert
Bipolar disorder heightens Parkinson risk, ADHD persistence may mediate bipolar spectrum disorder risk, and rapid cycling catalysts identified-these are some of the latest findings.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5